Compare Meta Platforms Inc (META) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Meta Platforms Inc vs GeneDx Holdings Corp — how do they compare? Meta Platforms Inc trades at $725.9 (market cap $1.84T), while GeneDx Holdings Corp trades at $67.6 (market cap $2.02B). The key difference: Meta Platforms Inc is far larger — about 910.9× GeneDx Holdings Corp's market cap, and Meta Platforms Inc pays a 0.29% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Meta Platforms Inc for 127 Days and GeneDx Holdings Corp for 19 Days on average.
| META | WGS | |
|---|---|---|
Market Cap | $1.84T | $2.02B |
Volume | 15,887,049 | 734,640 |
Sector | Media | Health |
52-Week High | $777.59 | $167.51 |
52-Week Low | $525.72 | $34.51 |
Typical Hold Time | 127 Days | 19 Days |
Enterprise Value | $1.86T | $2.05B |
Dividend Yield | 0.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
META stock trades at $721.31, down 2.38% on the day, amid a mixed technical and fundamental backdrop. The stock shows a bullish trend per moving averages, with key support at $719 and resistance at $726. Recent financials reveal strong revenue growth to $201.0B in 2025 and a net income margin of 29.84%, though Q2 2026 EPS missed expectations. The launch of the Muse Spark AI model and a $21B deal with CoreWeave highlight strategic initiatives driving investor optimism, countered by ongoing legal challenges over youth addiction.
The outlook for META remains positive with an 80% analyst buy rating and a consensus price target of $781, suggesting ~8% upside. Key opportunities include AI monetization and robust cash flow growth, while risks involve regulatory lawsuits and high capital expenditures. Investors should weigh strong profitability against legal and competitive pressures in the social media sector.
GeneDx Holdings Corp. (WGS) trades at $68.53, down 4.18% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported a net loss of $21.02 million for 2025, though Q2 2026 earnings beat expectations. Revenue growth is positive, but profitability remains a challenge with negative margins. Analyst consensus is strongly bullish with a $81.00 price target, supported by recent product launches and institutional interest.
The outlook hinges on execution toward profitability amid high cash burn. Investment opportunity lies in the genomic testing market expansion and analyst optimism, but risks include sustained losses, competitive pressure, and reliance on financing. The stock's trajectory will depend on achieving projected margin improvements and revenue scalability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
